Singapore, March 19 -- China-based startup Excalipoint Therapeutics, a biotechnology company developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases, has announced an oversubscribed $68.7 million seed financing round to support advancement of its proprietary technology platforms and pipeline of differentiated T-cell engager programs.

The financing includes $41 million in seed funding completed at the company's inception in August 2025, co-led by HSG, Apricot Capital, and Yuanbio Venture Capital, with participation from 5Y Capital, Co-Win Ventures, Med-Fine Capital and Hony Capital. The seed round represents one of the largest early-stage financings for a Chinese biotechnology company.

After ramping u...